CL2014002283A1 - Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor. - Google Patents
Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.Info
- Publication number
- CL2014002283A1 CL2014002283A1 CL2014002283A CL2014002283A CL2014002283A1 CL 2014002283 A1 CL2014002283 A1 CL 2014002283A1 CL 2014002283 A CL2014002283 A CL 2014002283A CL 2014002283 A CL2014002283 A CL 2014002283A CL 2014002283 A1 CL2014002283 A1 CL 2014002283A1
- Authority
- CL
- Chile
- Prior art keywords
- active agent
- core
- prepare
- particles
- coating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261606156P | 2012-03-02 | 2012-03-02 | |
US201261724141P | 2012-11-08 | 2012-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014002283A1 true CL2014002283A1 (es) | 2015-04-17 |
Family
ID=48044945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014002283A CL2014002283A1 (es) | 2012-03-02 | 2014-08-28 | Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor. |
Country Status (21)
Country | Link |
---|---|
US (2) | US11173155B2 (es) |
EP (2) | EP2819653B1 (es) |
JP (2) | JP6199321B2 (es) |
CN (2) | CN109820830A (es) |
AR (1) | AR090218A1 (es) |
AU (2) | AU2013203493B2 (es) |
CA (1) | CA2852042C (es) |
CL (1) | CL2014002283A1 (es) |
EA (1) | EA028224B1 (es) |
ES (2) | ES2821773T3 (es) |
IL (1) | IL234256B (es) |
IN (1) | IN2014MN01901A (es) |
MX (1) | MX354677B (es) |
NZ (1) | NZ629468A (es) |
PE (1) | PE20142320A1 (es) |
PH (1) | PH12014501910A1 (es) |
SG (1) | SG11201405011PA (es) |
TW (2) | TWI614037B (es) |
UY (1) | UY34651A (es) |
WO (1) | WO2013128276A2 (es) |
ZA (1) | ZA201405960B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
ES2570454T3 (es) | 2003-03-26 | 2016-05-18 | Egalet Ltd | Sistema de liberación controlada de morfina |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP2124556B1 (en) | 2006-10-09 | 2014-09-03 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
EP3311667A1 (en) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
CN102639118B (zh) | 2009-07-22 | 2015-07-29 | 格吕伦塔尔有限公司 | 氧化稳定的抗干扰剂型 |
ES2534908T3 (es) | 2009-07-22 | 2015-04-30 | Grünenthal GmbH | Forma de dosificación de liberación controlada extruida por fusión en caliente |
PL2611426T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie |
MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
RS56527B1 (sr) | 2011-07-29 | 2018-02-28 | Gruenenthal Gmbh | Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu |
DK2736495T3 (da) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel |
EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
MX362357B (es) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AU2014273226B2 (en) | 2013-05-29 | 2019-06-27 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
US20150118300A1 (en) * | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
EP3062778A4 (en) * | 2013-10-31 | 2017-07-19 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
BR112016010482B1 (pt) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | Preparação de uma composição farmacêutica em pó por meio de criomoagem |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2938699A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma Llc | Abuse-resistant drug formulations with built-in overdose protection |
MX2016014738A (es) | 2014-05-12 | 2017-03-06 | Gruenenthal Gmbh | Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol. |
CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
EP3229788A4 (en) | 2014-12-08 | 2018-06-13 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
AU2016251852A1 (en) * | 2015-04-24 | 2017-11-09 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder |
AU2016251302A1 (en) * | 2015-04-24 | 2017-11-23 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
CA2983640A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
CA2983642A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
JP2018515455A (ja) * | 2015-04-24 | 2018-06-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 粒子から2種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ |
WO2016200960A1 (en) * | 2015-06-09 | 2016-12-15 | KVK-Tech, Inc. | Abuse deterrent pharmaceutical compositions |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3522890A4 (en) * | 2016-10-10 | 2020-06-03 | Rhodes Pharmaceuticals L.P. | RESINATE-BASED PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME |
EP3558300B1 (en) * | 2016-12-21 | 2021-11-24 | Tioga Pharmaceuticals, Inc. | Solid pharmaceutical formulations of asimadoline |
US11690840B2 (en) | 2017-10-09 | 2023-07-04 | Rhodes Pharmaceuticals L.P. | Pharmaceutical resinate compositions and methods of making and using thereof |
US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
CN117715538A (zh) * | 2021-05-03 | 2024-03-15 | 剑桥糖质科学有限公司 | 可溶性糖和不溶性糖的组合物及相关方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2530563C2 (de) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US6740341B1 (en) | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
TWI256309B (en) * | 1999-10-13 | 2006-06-11 | Akzo Nobel Nv | New formulation of mirtazapine |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
DE20220917U1 (de) * | 2001-08-06 | 2004-08-19 | Euro-Celtique S.A. | Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden |
US20030068276A1 (en) * | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US20040091544A1 (en) | 2002-11-08 | 2004-05-13 | Ruff Michael D. | Coated dibasic calcium phosphate |
CA2513893A1 (en) | 2003-01-28 | 2004-08-12 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
FR2850576B1 (fr) | 2003-02-05 | 2007-03-23 | Ethypharm Sa | Composition comprenant un melange de principes actifs, et procede de preparation |
US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
ATE544447T1 (de) * | 2003-09-26 | 2012-02-15 | Alza Corp | Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung |
PT2210605T (pt) * | 2003-11-04 | 2017-04-24 | Tcd Royalty Sub Llc | Formas de dosagem única diária de tróspio |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
TWI365880B (en) | 2004-03-30 | 2012-06-11 | Euro Celtique Sa | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp |
US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
CA2608361A1 (en) * | 2005-05-13 | 2006-11-23 | Alpharma, Inc. | Morphine sulphate formulations |
ZA200805646B (en) * | 2005-12-28 | 2009-12-30 | Takeda Pharmaceutical | Controlled release solid preparation |
US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
WO2007120135A1 (en) * | 2006-04-17 | 2007-10-25 | Forest Laboratories, Inc. | Lercanidipine immediate release composition |
CL2007001194A1 (es) * | 2006-04-27 | 2008-01-04 | Takeda Pharmaceutical | Preparacion farmaceutica solida que comprende particulas que comprenden (i) particulas de nucleo con excipiente y (ii) pioglitazona o una sal de la misma y un polimero soluble en acido, como copolimero de aminoalquil metacrilato e o dietilaminoacetato de polivinilacetal, ambos recubriendo el nucleo |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
FR2904225B1 (fr) * | 2006-07-28 | 2010-08-13 | Bouchara Recordati | Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
US20100151034A1 (en) * | 2008-09-30 | 2010-06-17 | Astellas Pharma Inc. | Granular pharmaceutical composition of atorvastatin for oral administration |
WO2010044842A1 (en) * | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
BRPI0917608B8 (pt) * | 2008-12-12 | 2021-05-25 | Paladin Labs Inc | formulação de droga oral para a redução de potencial efeito abusivo, processo para a fabricação de uma formulação de droga e seu uso |
WO2010069050A1 (en) * | 2008-12-16 | 2010-06-24 | Labopharm Inc. | Misuse preventative, controlled release formulation |
WO2011041414A1 (en) | 2009-09-30 | 2011-04-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
BR112012010102B8 (pt) * | 2009-10-28 | 2021-05-25 | Basf Se | material de revestimento, uso de materiais de revestimento, e, revestimentos de película para formas de dosagem farmacêuticas |
AU2012275115A1 (en) | 2011-06-29 | 2014-01-30 | Allergan, Inc. | Macrogol 15 hydroxystearate formulations |
US20140341984A1 (en) * | 2011-09-16 | 2014-11-20 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
-
2013
- 2013-03-01 PE PE2014001346A patent/PE20142320A1/es not_active Application Discontinuation
- 2013-03-01 ES ES17150886T patent/ES2821773T3/es active Active
- 2013-03-01 AR ARP130100669A patent/AR090218A1/es unknown
- 2013-03-01 EP EP13713496.1A patent/EP2819653B1/en active Active
- 2013-03-01 TW TW102107275A patent/TWI614037B/zh not_active IP Right Cessation
- 2013-03-01 CN CN201910170603.9A patent/CN109820830A/zh active Pending
- 2013-03-01 SG SG11201405011PA patent/SG11201405011PA/en unknown
- 2013-03-01 CA CA2852042A patent/CA2852042C/en active Active
- 2013-03-01 CN CN201380012104.8A patent/CN104144681A/zh active Pending
- 2013-03-01 WO PCT/IB2013/000444 patent/WO2013128276A2/en active Application Filing
- 2013-03-01 JP JP2014559310A patent/JP6199321B2/ja active Active
- 2013-03-01 IN IN1901MUN2014 patent/IN2014MN01901A/en unknown
- 2013-03-01 EP EP17150886.4A patent/EP3170492B1/en active Active
- 2013-03-01 TW TW105127500A patent/TW201722406A/zh unknown
- 2013-03-01 NZ NZ629468A patent/NZ629468A/en not_active IP Right Cessation
- 2013-03-01 EA EA201400972A patent/EA028224B1/ru not_active IP Right Cessation
- 2013-03-01 AU AU2013203493A patent/AU2013203493B2/en active Active
- 2013-03-01 UY UY0001034651A patent/UY34651A/es not_active Application Discontinuation
- 2013-03-01 ES ES13713496.1T patent/ES2619574T3/es active Active
- 2013-03-01 MX MX2014010534A patent/MX354677B/es active IP Right Grant
- 2013-03-01 US US14/377,900 patent/US11173155B2/en active Active
-
2014
- 2014-08-14 ZA ZA2014/05960A patent/ZA201405960B/en unknown
- 2014-08-21 IL IL234256A patent/IL234256B/en active IP Right Grant
- 2014-08-22 PH PH12014501910A patent/PH12014501910A1/en unknown
- 2014-08-28 CL CL2014002283A patent/CL2014002283A1/es unknown
-
2016
- 2016-05-04 AU AU2016202846A patent/AU2016202846B2/en active Active
-
2017
- 2017-08-23 JP JP2017159995A patent/JP6509287B2/ja active Active
-
2021
- 2021-10-14 US US17/501,641 patent/US20220031693A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014002283A1 (es) | Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor. | |
CL2014001070A1 (es) | Compuestos derivados de aminoácidos funcionalizados en el n-terminal, capaces de formar micro- o nanopartículas para encapsular un agente; composición; uso para tratar enfermedades; y método de suministro de un polinucleótido a una célula. | |
CL2013001120A1 (es) | Una dispersion solida que comprende un agente inductor de apoptosis de formula definida dispersado en una matriz solida que comprende a) al menos un vehiculo polimerico soluble en agua y b) al menos un surfactante; proceso de preparacion; forma de dosificacion oral, util para tratar una enfermedad neoplasica, inmune o autoinmune. | |
CL2014001450A1 (es) | Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor. | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112013023175A2 (pt) | composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto | |
CL2014001172A1 (es) | Un portador para la liberacion controlada de agentes activos que comprende un nucleo de cabonato de calcio y un agente activo, y un recubrimiento que encapsula al nucleo; metodo para preparar el portador, y su uso en controlar la liberacion de un agente activo | |
CL2012002909A1 (es) | Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral | |
CL2014002795A1 (es) | Una formulacion de farmaco de liberacion retardada oral para suministrar un farmaco al colon que comprende un nucleo y un recubrimiento para el nucleo, el nucleo comprende un farmaco y el recubrimiento comprende una capa exterior con una mezcla de un primer y segundo material polimerico y una capa interior con un tercer material polimerico; y su metodo de preparacion. | |
BR112014009634A2 (pt) | preparação e agente terapêutico | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112012015540A2 (pt) | composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto | |
BR112013018953A2 (pt) | composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais. | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
BR112013014169A2 (pt) | composição para uso em cápsulas de moldagem por revestimento externo e método de formação da composição | |
BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
CL2013002033A1 (es) | Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. | |
BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
CL2014000844A1 (es) | Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada. | |
AR083208A1 (es) | Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion | |
ZA201508454B (en) | Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component | |
BR112014028723A2 (pt) | forma cristalina, seu processo de produção e mistura, agente de proteção, uso da forma cristalina e método para o combate | |
GT201200304A (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. |